Phreesia Inc

Phreesia Inc(PHR)股票分析

$12.050

+0.823 (+6.83%)收盤時

Loading chart…
最高
12.060
開盤
11.320
成交量加權均價
11.80
成交量
1.00M
市值
1.21B
最低
11.295
成交金額
11.82M
企業價值/稅息折舊攤銷前利潤(TTM)
9.83

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.

AI 分析 of Phreesia Inc (PHR)

持有

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

估值指標

Phreesia Inc(PHR)目前預期本益比為 12.02,5 年平均預期本益比為 3.94。

預期本益比

合理
5 年均值 P/E
3.94
目前P/E
12.02
高估
193.22
低估
-185.34

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-21.53
目前EV/EBITDA
9.83
高估
98.35
低估
-141.41

預期股價營收比

低估
5 年均值 P/S
3.61
目前P/S
1.27
高估
5.91
低估
1.31

Alphio AI 對 PHR 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%PHR

$23.17

情境價格

基

基準

基準 · 50%PHR

$22.64

情境價格

悲

悲觀

悲觀 · 25%PHR

$21.67

情境價格

持有 PHR 的大戶

P

Pale Fire Capital SE

+ 持有PHR

+0.03%

3個月報酬率

事件時間軸

2026-09-02 (ET)

19:30:00

Major Indices Bounce Back as ADP Employment Data Falls Short

16:30:00

Phreesia Reports Q2 Revenue of $129.5M, Beating Expectations

2026-06-11 (ET)

14:30:00

Jeff Bezos' New AI Venture Prometheus Raises $12B, Valuation Reaches $41B

2026-05-27 (ET)

19:50:00

WTI Crude Oil Falls Below $90, Energy Sector Worst Performer

16:30:00

Phreesia Maintains Fiscal 2027 Revenue Outlook at $510M to $520M

資訊

PHR 常見問題 —— 由 Alphio AI 解答

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易